Modality
Nanobody
MOA
PD-1i
Target
EZH2
Pathway
Checkpoint
LNSCD
Development Pipeline
Preclinical
~May 2018
→ ~Aug 2019
Phase 1
~Nov 2019
→ ~Feb 2021
Phase 2
May 2021
→ Feb 2031
Phase 2Current
NCT07809491
1,427 pts·LN
2021-05→2031-02·Terminated
1,427 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-02-164.9y awayPh3 Readout· LN
Trial Timeline
Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
P2/3
Termina…
Catalysts
Ph3 Readout
2031-02-16 · 4.9y away
LN
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07809491 | Phase 2/3 | LN | Terminated | 1427 | SRI-4 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| GSK-7987 | GSK | Phase 3 | MDM2 | |
| DSN-2247 | Daiichi Sankyo | NDA/BLA | EZH2 | |
| Nirabrutinib | BioNTech | Phase 2/3 | CDK2 | |
| Cevinaritide | Genmab | Phase 2/3 | DLL3 | |
| HAL-9635 | Halozyme | Phase 2/3 | EZH2 | |
| ZYM-2450 | Zymeworks | Phase 2 | GLP-1R | |
| Voxabrutinib | Annexon | Phase 1/2 | EZH2 | |
| SLD-1824 | Solid Bio | Phase 2 | EZH2 | |
| Nidarelsin | Uniqure | Phase 2/3 | RET | |
| EXA-971 | Exscientia | Phase 2 | CGRP |